← Back to Search

Opioid

Methadone for Cancer Pain (METHADOPT Trial)

Phase 3
Waitlist Available
Led By Bruno Gagnon, MD MSc
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cancer type is adenocarcinoma;
In the physician's opinion, mechanism of pain is most likely linked to an adenocarcinoma 'in proximity to' or invading a nerve or nerve plexus (i.e., 'adenocarcinopathic' pain; ACPP);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

METHADOPT Trial Summary

This trial will compare the effectiveness of methadone to morphine in treating a specific type of cancer pain.

Eligible Conditions
  • Cancer Pain
  • Adenocarcinoma

METHADOPT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

METHADOPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Global change
Pain control
Pain relief
+3 more

METHADOPT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MethadoneExperimental Treatment1 Intervention
DESCRIPTION: Blinded methadone 1mg tablets PO -- DOSAGE: A) For patients initially taking 0-30 mg MEDD: Starting dose: 0.5mg Q4H x 4 doses + 1.0mg QHS + 0.5mg Q2H PRN (max 4 doses) First increase: 1.0 mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses) Second increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 0.5mg Q2H PRN (max 4 doses) Third increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses) Fourth increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.0mg Q2H PRN (max 4 doses) B) For patients initially taking 31-60 mg MEDD: Starting dose: 1.0mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses) First increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 1.0mg Q2H PRN (max 4 doses) Second increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses) Third increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.5mg Q2H PRN (max 4 doses) Fourth increase: 3.0mg Q4H x 4 doses + 6.0mg QHS + 1.5mg Q2H PRN (max 4 doses)
Group II: MorphineActive Control1 Intervention
DESCRIPTION: Blinded morphine 5mg tablets PO -- DOSAGE: A) For patients initially taking 0-30 mg MEDD: Starting dose: 2.5mg Q4H x 4 doses + 5.0mg QHS + 2.5mg Q2H PRN (max 4 doses) First increase: 5.0 mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses) Second increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 2.5mg Q2H PRN (max 4 doses) Third increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses) Fourth increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 5.0mg Q2H PRN (max 4 doses) B) For patients initially taking 31-60 mg MEDD: Starting dose: 5.0mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses) First increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 5.0mg Q2H PRN (max 4 doses) Second increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses) Third increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 12.5mg Q2H PRN (max 4 doses) Fourth increase: 15.0mg Q4H x 4 doses + 30.0mg QHS + 12.5mg Q2H PRN (max 4 doses)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Methadone
FDA approved

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,691 Total Patients Enrolled
The Ottawa HospitalOTHER
93 Previous Clinical Trials
62,988 Total Patients Enrolled
Bruyere Research InstituteOTHER
34 Previous Clinical Trials
2,024,219 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial open to patients who are not yet 50 years old?

"The age restrictions for participants in this trial are that they must be over 18 years old but under 75 years old."

Answered by AI

Are there currently any open positions in this clinical trial?

"According to clinicaltrials.gov, this trial is not presently looking for patients. This study was originally posted on June 1st, 2022 and was last updated on April 13th, 2022. Although this trial is not currently recruiting, there are 814 other trials that are."

Answered by AI

Are there any specific eligibility requirements for this clinical trial?

"This clinical trial is looking for 40 participants aged 18 to 75 who are currently experiencing cancer pain. In addition to cancer pain, the following inclusion criteria must be met: Cancer type is adenocarcinoma;, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2;, Estimated prognosis of at least 3 months;, Able to fill out questionnaires and understand procedures in English and/or French;, Able to provide first person informed consent;, Physician deems it appropriate to start the patient on the opioid., In the physician's opinion, mechanism of pain is most likely linked to"

Answered by AI
Recent research and studies
~0 spots leftby Mar 2025